Premium
Neurofilament heavy‐chain NfH SMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
Author(s) -
Brettschneider Johannes,
Petzold Axel,
Süßmuth Sigurd D.,
Landwehrmeyer Georg B.,
Ludolph Albert C.,
Kassubek Jan,
Tumani Hayrettin
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.21124
Subject(s) - progressive supranuclear palsy , corticobasal degeneration , cerebrospinal fluid , differential diagnosis , pathology , atrophy , medicine , degenerative disease , biomarker , parkinson's disease , disease , chemistry , biochemistry
Abstract We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH SMI35 in the laboratory‐supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple‐system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age‐matched controls (n = 45) were included. CSF levels of NfH SMI35 were measured using ELISA. Levels of CSF NfH SMI35 were elevated in PSP compared to PD and controls ( P < 0.05 each). They were also significantly higher in MSA than in PD and controls ( P < 0.05 each). NfH SMI35 differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH SMI35 is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH SMI35 may therefore be of some value for the laboratory‐supported differential diagnosis of atypical parkinsonian syndromes. © 2006 Movement Disorder Society